FDA delays approval for BMS cancer therapy

Bristol-Myers said the marketing application submitted to the U.S. FDA for its Opdivo plus Yervoy cancer therapy combination will be delayed by three months, until May 2019.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news